secwatch.observer — SEC 8-K summary
======================================

Issuer:     enVVeno Medical Corp (NVNO)
CIK:        0001661053
Form:       8-K
Filed at:   2021-09-22T23:59:59+00:00
Accession:  0001493152-21-023320
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Hancock Jaffe to rename enVVeno Medical, focus on venous disease; VenoValve trial to start
--------------------------------------------------------------------------------

- Name change to enVVeno Medical Corporation, tickers NVNO/NVNW effective Oct 1, 2021.
- VenoValve SAVVE pivotal trial ready to enroll 75 patients at up to 20 U.S. centers.
- Development of second venous disease product 'enVVe' initiated; expected unveil mid-2022.
- CoreoGraft cardiac bypass program discontinued to focus on venous disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661053/000149315221023320/0001493152-21-023320-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661053/000149315221023320/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-21-023320

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer